Scarica l'app Stockscreener
8.95
7.73%
-0.75
Spruce Biosciences Inc Borsa (SPRB) Ultime notizie
Critical Contrast: Spruce Biosciences (SPRBD) vs. Its Rivals - Defense World
Reviewing Spruce Biosciences (SPRBD) & Its Rivals - Defense World
Spruce Biosciences, Inc.(NasdaqCM: SPRB) added to NASDAQ Composite Index - MarketScreener
Spruce Biosciences Resumes Trading on the Nasdaq Capital Market - BioSpace
Spruce Biosciences resumes Nasdaq trading today - Investing.com
Spruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy Demonstrating Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B - Investing News Network
One new option listing and two option delistings on September 5th - TipRanks
Head to Head Contrast: Spruce Biosciences (SPRBD) versus Its Peers - Defense World
Spruce Biosciences (SPRBD) & The Competition Critical Review - Defense World
Spruce Biosciences (SPRBD) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - sharewise.com
Spruce Biosciences (NASDAQ:SPRB) Trading Down 1.6% – What’s Next? - Defense World
Contrasting Spruce Biosciences (SPRBD) and The Competition - Defense World
Financial Analysis: MusclePharm (OTCMKTS:MSLP) & Spruce Biosciences (NASDAQ:SPRB) - Defense World
Research Analysts Set Expectations for OTC:SPRBD Q1 Earnings - Defense World
Spruce Biosciences Reports Promising Clinical Advances - TipRanks
Cautious Optimism for Spruce Biosciences Amid Promising Data and Financial Uncertainty - TipRanks
Head to Head Survey: Zomedica (OTC:ZOMDF) vs. Spruce Biosciences (NASDAQ:SPRB) - Defense World
Spruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Demonstrating Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B (MPS IIIB) - BioSpace
Spruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates - BioSpace
Spruce Biosciences reports positive long-term data for MPS IIIB therapy - Investing.com Nigeria
Spruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Demonstrating Profound and Durable Efficacy and Safety in Patients with Sanfil - StreetInsider
Spruce Biosciences (SPRB) Expected to Announce Earnings on Monday - Defense World
Head to Head Analysis: Gemini Therapeutics (NASDAQ:GMTX) and Spruce Biosciences (NASDAQ:SPRB) - Defense World
Curis (CRIS) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Press Release: Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates - 富途牛牛
Spruce Biosciences (NASDAQ:SPRB) Shares to Reverse Split on Monday, August 4th - Defense World
Spruce Biosciences Announces Reverse Stock Split Plan - The Globe and Mail
Spruce Biosciences to enact 1-for-75 reverse stock split - MSN
Spruce Biosciences to implement 1-for-75 reverse stock split - Investing.com
Spruce Biosciences Announces Reverse Stock Split - Business Wire
HMNC Brain Health and Spruce Biosciences Announce First Patient Dosed in Phase 2 TAMARIND Trial For Major Depressive Disorder - The Manila Times
Spruce Biosciences (SPRB) Advances in Phase 2 Depression Treatme - GuruFocus
Spruce Biosciences (NASDAQ:SPRB) Trading Up 5.7% – Here’s What Happened - Defense World
Layoff Tracker: Following Challenges With DMD Therapy, Sarepta Will Cut 500 Employees - BioSpace
New weight reduction data for Crenessity presented by Neurocrine - The Pharma Letter
Ultragenyx hit again, this time with a CRL in rare disease - BioWorld MedTech
Spruce Biosciences (SPRB) Gains Investor Attention with Significant Interest Surge | SPRB Stock News - GuruFocus
Spruce Biosciences gets conditional approval to resume trading on Nasdaq Capital Market - MSN
Spruce Biosciences (NASDAQ:SPRB) versus Pharmaxis (OTCMKTS:PXSLY) Head-To-Head Analysis - Defense World
Congenital Adrenal Hyperplasia Treatment Market Outlook Influenced by Gene Therapy Innovations 2025 - openPR.com
SPRB ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Spruce Biosciences, Inc. - ACCESS Newswire
BriaCell Therapeutics (OTCMKTS:BCTXF) vs. Spruce Biosciences (NASDAQ:SPRB) Head-To-Head Survey - Defense World
Congenital Adrenal Hyperplasia Pipeline Insight, 2025: - openPR.com
Spruce Biosciences (SPRB) Secures Nasdaq Approval for Relisting - GuruFocus
Spruce Biosciences Announces Conditional Nasdaq Approval to Resu - GuruFocus
# Spruce Biosciences to resume Nasdaq trading pending stock split approval By Investing.com - Investing.com South Africa
2.36%
1.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):